Appeal guide · Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda

Denied for Wegovy or Zepbound? Most GLP-1 denials are paperwork, not medicine.

The denial letter has a reason code. Read it correctly and the next step is usually a specific missing document, not an argument. This page decodes the six common codes, lists the documents that answer them, and gives you the deadline that applies.

Start appeal Free deadline check

$0 upfront. 10% of what we recover, no cap. Nothing if we don't. · Reviewed by the Apellica Editorial Team · Sep 4, 2026

Quick answer (60 seconds)

Find the reason code on your letter. If it is about criteria, BMI, comorbidities, step therapy or quantity, the fix is documentation and a letter of medical necessity that answers that exact code. If it is a plan exclusion for weight loss, a medical-necessity appeal usually cannot override it; the only reliable openings are the labeled non-weight indications (Wegovy for cardiovascular risk reduction or MASH, Zepbound for obstructive sleep apnea) when your clinician has documented them. Employer and ACA plans give at least 180 days to appeal; Medicare Part D gives 60 days. This is general information, not legal or medical advice.

Read your denial reason code

Insurers reuse a small set of reasons for GLP-1 denials. Each one means something specific about what the reviewer could and could not find in your file.

Reason on the letter	What it actually means	What fixes it
Not medically necessary	The reviewer could not find, in what was submitted, the plan's own prior-authorization criteria being met. It is usually a documentation verdict on the file, not a clinical verdict on you.	Get the plan's written GLP-1 criteria (you can request the rule relied on; see the claim-file letter below). Have your prescriber write a letter of medical necessity that answers each criterion by name with a dated chart entry.
BMI or comorbidity documentation missing	The chart did not clearly show the labeled threshold, a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, or the condition was mentioned but not coded and dated.	Attach dated height/weight/BMI readings over time, the comorbidity with its ICD-10 code (for example hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) and the supporting labs or study (A1c, lipids, blood pressure, sleep study).
Step therapy not tried	The plan requires a documented trial of a preferred option first, often a supervised lifestyle program for 3 to 6 months, or a lower-cost drug, before it will cover the requested GLP-1.	Pharmacy and chart records of what was tried, for how long, and why it failed or was contraindicated. Fully-insured plans in many states are also subject to state step-therapy override laws; self-funded employer plans and Medicare generally are not. See the step-therapy guide linked below.
Plan exclusion for weight loss	This is benefit design, not a medical judgment. The plan does not cover anti-obesity medication as a category. A medical-necessity appeal usually cannot override a true exclusion, and we will tell you that honestly.	Check whether a labeled indication other than weight loss applies and is documented by your clinician on the record: Wegovy for cardiovascular risk reduction (FDA, March 2024) or MASH (FDA, August 2025); Zepbound for obstructive sleep apnea (FDA, December 2024). If none applies, the realistic route is a formulary exception request plus asking HR to add the benefit at open enrollment.
Off-label for OSA or CV risk	The reviewer treated the indication as off-label. Sometimes that is wrong: OSA is on the Zepbound label and cardiovascular risk reduction is on the Wegovy label. Sometimes it is right: Ozempic and Mounjaro are type 2 diabetes labels, and the weight-management indications belong to Wegovy and Zepbound.	Match the drug to the label. If the indication is on the label, cite the label section and the qualifying diagnosis (established cardiovascular disease with overweight or obesity for Wegovy; moderate-to-severe OSA with obesity for Zepbound). If the drug is being used off-label, the appeal is weaker and a labeled alternative may be the better request; your prescriber decides.
Quantity limit	The prescribed quantity exceeds the plan's per-fill cap, which often happens during dose titration or when a 90-day supply is written against a 28-day limit.	A quantity-limit exception with a prescriber statement tying the quantity to the label's titration schedule or maintenance dose. See the quantity-limit guide linked below.

Honest limit: a true plan exclusion for weight-loss drugs is a benefit-design decision. Appeals on medical necessity generally cannot force coverage of an excluded category. The exceptions are the labeled indications that are not weight loss, and only when your treating clinician has established that diagnosis on the record. A diagnosis is never selected to obtain coverage.

The 3 documents that win, plus the letter that ties them together

Document 1

BMI history

Dated height, weight and BMI readings, ideally several over 6 to 12 months. A single number on the day of the visit is the most common gap.

Document 2

Comorbidity documentation

Each weight-related condition named, coded (ICD-10) and supported: labs for diabetes and lipids, blood-pressure readings for hypertension, a sleep study with AHI for OSA, cardiology records for established cardiovascular disease.

Document 3

Prior attempts and step-therapy record

What was tried before (lifestyle program, prior medications), the dates, the result, and any contraindication to the preferred alternative. Pharmacy claims history is the cleanest evidence.

The letter

A letter of medical necessity that answers the exact reason code

Not a generic letter. It quotes the plan's criterion, then points to the chart entry that satisfies it, one criterion at a time, and states the labeled indication being treated.

Before you appeal, you can demand the plan's own criteria and the reviewer's identity. Generate a free claim-file request letter.

Deadlines by plan type

These are the federal floors. The date printed on your denial letter and your plan documents control, and expedited (urgent) requests run on much shorter clocks.

Employer plan (ERISA)

At least 180 days from receipt of the denial to file the internal appeal.

Source: 29 CFR 2560.503-1(h)(3)(i)

If the final internal denial stands, external review by an independent review organization; the federal window is generally 4 months from the final denial (45 CFR 147.136(d)). Self-funded plans use the federal external-review process rather than a state program.

Individual / ACA marketplace plan

At least 180 days to file the internal appeal.

Source: 45 CFR 147.136(b)

Then state external review (or the federal process where the state has none). Windows and forms vary by state; see the external-review index.

Medicare Part D

60 days from the date of the coverage-determination notice to request a redetermination.

Source: 42 CFR 423.582(b)

If upheld, reconsideration by the Independent Review Entity, then further levels. Note: Part D excludes drugs used for weight loss by statute (42 U.S.C. 1395w-102(e)(2)(A), incorporating 42 U.S.C. 1396r-8(d)(2)(A)); CMS guidance dated March 20, 2024 confirmed a GLP-1 may be covered under Part D when prescribed for a different medically accepted indication, such as cardiovascular risk reduction.

Estimate my deadline State external-review index

Frequently asked questions

Is a Wegovy denial worth appealing?

Often, if the denial is about documentation (criteria not shown, BMI or comorbidity missing, step therapy not recorded). Those reasons can be answered with records. If the denial is a plan-level exclusion of anti-obesity drugs, an appeal on medical necessity usually cannot override it, and the question becomes whether a labeled non-weight indication applies to you and is documented by your clinician.

My plan excludes weight-loss drugs. Can I still get Wegovy or Zepbound covered?

Sometimes, and only when a separately labeled indication applies and is established by your clinician on the medical record: Wegovy carries FDA indications for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity (March 2024) and for MASH with moderate-to-advanced fibrosis (August 2025); Zepbound carries an indication for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). A diagnosis is never chosen to obtain coverage. If none applies, the appeal cannot rewrite the benefit, and we say so.

Ozempic and Mounjaro were denied for weight loss. What now?

Ozempic and Mounjaro are FDA-labeled for type 2 diabetes, not for chronic weight management. A plan that limits them to their labeled indication is applying the label. If you have type 2 diabetes, the appeal should document it and the plan's diabetes criteria. If the goal is weight management, Wegovy or Zepbound is the labeled product, and your prescriber may prefer to request that instead.

How long do I have to appeal a GLP-1 denial?

Employer (ERISA) and ACA plans must give you at least 180 days to file an internal appeal (29 CFR 2560.503-1 and 45 CFR 147.136). Medicare Part D gives 60 days from the coverage-determination notice to request a redetermination (42 CFR 423.582). The date on your denial letter controls; use the free deadline calculator to estimate yours.

What does a letter of medical necessity for a GLP-1 need to say?

It should name the labeled indication being treated, state the BMI and the qualifying comorbidity with dates and codes, list the prior treatments tried and their results, and answer each of the plan's written criteria in turn. Your prescriber writes it; a good draft points them to the exact chart entries.

What does Apellica charge?

$0 upfront. 10% of what we recover, no cap. Nothing if we don't. We are not a law firm and do not provide legal advice; we help you prepare, file and track the appeal, and we do not guarantee any outcome.

Sources

Denied for a GLP-1? We prepare and file the appeal.

$0 upfront. 10% of what we recover, no cap. Nothing if we don't. Two-minute intake; we confirm fit within one business day and tell you plainly if the denial is a plan exclusion we cannot appeal.

Start appeal

Drug-specific guides

Pharmacy appeal guides

This page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Whether a GLP-1 is appropriate for you, and which indication applies, is a decision for you and your prescriber. Outcomes depend on documentation, plan terms, and timing.